The combined expression of Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer

• Published in: BMC cancer 2016-07, Vol.16 (1), p.525-525, Article 525
• Main Authors: Ikeya, Tetsuro, Maeda, Kiyoshi, Nagahara, Hisashi, Shibutani, Masatsune, Iseki, Yasuhito, Hirakawa, Kosei
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antigens, CD - metabolism; Biomarkers, Tumor - metabolism; Chemotherapy, Adjuvant; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Complications and side effects; Disease-Free Survival; Diseases; Female; Humans; Influence; Kaplan-Meier Estimate; Lymphatic Metastasis; Lymphatic system; Male; Metastasis; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - prevention & control; Nerve Tissue Proteins - metabolism; Polyclonal antibodies; Prognosis; Receptors, Cell Surface - metabolism; Relapse; Risk Factors; Semaphorins; Semaphorins - metabolism; Survival analysis; Treatment Outcome; Tumors; Young Adult
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-016-2577-6

Binding to Sema4D and PlexinB1 induce angiogenesis and invasive growth in colorectal cancer (CRC). The expression of Semaphorin4D (Sema4D) and PlexinB1 has been shown to be related to the prognosis of patients with various malignancies. However, the correlation between the expression of Sema4D and PlexinB1 and the relapse-free survival in patients with colorectal cancer remains controversial. The study population included patients who underwent surgery for colorectal cancer (n = 226). The expression of Sema4D and PlexinB1 were analyzed by immunohistochemistry in tissue of stage I, II, and III colon cancers. The immunohistochemical staining of colorectal cancer tissue specimens revealed that 95 (42 %) and 105 (46.4 %) of the specimens were positive for Sema4D and PlexinB1. The expression of Sema4D and PlexinB1 respectively were both found to be significantly related to stage, depth of tumor invasion, lymph node metastasis, lymphatic invasion, and venous invasion, respectively. Sixty-three patients (27.9 %) expressed both Sema4D and PlexinB1. The positive expression of both Sema4D and PlexinB1 was found to be an independent risk factor for a worse survival (HR 1.079, CI 1.013-2.868; P = 0.044). The combination of Sema4D and PlexinB1 protein detected by immunohistochemistry was therefore useful for predicting disease recurrence in CRC patients.